Is BPC-157 Legal? What the FDA Actually Says in 2026

BPC-157 shows up on more Houston clinic menus than almost any other peptide — sold as an injectable for gut healing, tendon and joint recovery, or general inflammation. It’s also one of the most misrepresented substances in the industry, because its regulatory status changed twice in 2026 and neither change means what most sellers imply.

What it is

BPC-157 (“Body Protection Compound-157”) is a synthetic peptide based on a fragment of a protein found in human gastric juice. It has no FDA-approved use for any condition, in any form. There is no brand-name or generic BPC-157 drug on the market, and it has no monograph in the U.S. Pharmacopeia — the reference standard the FDA looks to when deciding whether a bulk substance is fit for compounding.

The FDA status, in order

Before April 2026: BPC-157 sat in “Category 2” of the FDA’s interim policy on bulk drug substances nominated for compounding — the list of substances the agency determined “may present significant safety risks.” The stated concerns: a risk of immunogenicity depending on the route of administration, and unresolved complexities in characterizing peptide-related impurities and the active pharmaceutical ingredient itself.

April 2026: The nomination was withdrawn from Category 2. As of this writing, FDA’s own page on Category 2 substances lists BPC-157 under “bulk drug substances nominated but withdrawn,” not under active substances the agency currently flags as high-risk. That is a narrower change than it sounds — withdrawal from Category 2 removes a specific safety-risk designation, but it does not add BPC-157 to the 503A Bulks List, the actual positive list a substance needs to be on before a compounding pharmacy can use it routinely, outside a documented patient-specific need.

July 23–24, 2026: The FDA’s Pharmacy Compounding Advisory Committee (PCAC) met at its White Oak campus and formally considered BPC-157 (free base and acetate) for addition to the 503A Bulks List, specifically evaluated for use in ulcerative colitis. Trade press covering the meeting (RAPS, AJMC) reported that FDA’s own staff recommended against adding it, citing a lack of efficacy data and randomized controlled trials, and that the committee itself narrowly voted to recommend inclusion anyway.

Where that leaves it today: an advisory committee recommendation is not FDA action. We checked the FDA’s 503A Bulks List page directly, and as of this writing BPC-157 is not on it. Adding a substance requires formal notice-and-comment rulemaking, a process the agency has said will take additional months. Until that’s finished, routine bulk compounding of BPC-157 remains outside what section 503A permits absent a documented, patient-specific medical rationale — the same standard that applies to compounded GLP-1s.

What this means for a clinic menu

“FDA is reviewing BPC-157” is true. “BPC-157 is FDA-approved” or “BPC-157 is now legal to compound” is not, and a clinic that markets it that way is either misinformed or misrepresenting an advisory committee vote as a finished rule.

Red flags we check for

No documented patient-specific need. A clinic offering BPC-157 as a standing “recovery” or “wellness” injection to any patient who asks — rather than compounding it for a specific, documented medical circumstance — is operating outside what the law currently allows.

Research-use-only vials sold with human dosing instructions. This is the more common pattern in Houston. Vendors label BPC-157 “for research purposes only” or “not for human consumption” while the clinic selling it provides injection instructions and a dosing schedule. The label is a legal fig leaf, not a safety measure.

No named prescriber behind the offering. The same test we apply to every clinic in this directory applies here: if you can’t verify who is prescribing it and under what documented rationale, the “medical” part of the program isn’t real.

This is exactly the pattern that disqualifies a clinic from our directory — a peptide menu built on research-only compounds with no FDA-approved indication is one of the two most common reasons we exclude a Houston clinic outright.

Browse our verified GLP-1 and peptide clinics in Houston, read what disqualifies a clinic and why, and see our full verification standard.

---

Sources: U.S. Food and Drug Administration, “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks” (Category 2 list, BPC-157 listed under substances nominated but withdrawn), retrieved September 4, 2026. FDA, “Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act” (503A Bulks List; BPC-157 not present), dateModified May 14, 2026, retrieved September 4, 2026. FDA, “July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee”, retrieved September 4, 2026. Regulatory Affairs Professionals Society (RAPS), “FDA advisory committee backs two controversial peptides”, on the committee’s recommendation regarding BPC-157, retrieved September 4, 2026.

This article is independent editorial content, not medical advice. See our medical disclaimer.